iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma
Kate Dixon(University of Minnesota), Bruce Walcheck(University of Veterinary Science), Bryan Hancock(Fate Therapeutics (United States)), Ryan Bjordahl(Fate Therapeutics (United States)), Jeffrey S. Miller(Science Museum of Minnesota), Soheila Shirinbak(Fate Therapeutics (United States)), Jianming Wu(Guangxi Academy of Agricultural Science), Zachary Davis(University of Minnesota), Bahram Valamehr(Fate Therapeutics (United States)), Melissa Khaw(University of Minnesota), Martin Hosking(Fate Therapeutics (United States)), Robert Hullsiek(University of Minnesota), Kristin M. Snyder(University of Minnesota), Anders W. Matson(University of Minnesota)
Cited by 7
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195